Cargando…
In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile
BACKGROUND: Polymethyl-methacrylate (PMMA) beads releasing antibiotics are used extensively to treat osteomyelitis, but require surgical removal afterwards because they do not degrade. METHODS: As an alternative option, this report compares the in vitro gentamicin release profile from clinically use...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459860/ https://www.ncbi.nlm.nih.gov/pubmed/16504140 http://dx.doi.org/10.1186/1471-2474-7-18 |
_version_ | 1782127497769385984 |
---|---|
author | Stallmann, Hein P Faber, Chris Bronckers, Antonius LJJ Nieuw Amerongen, Arie V Wuisman, Paul IJM |
author_facet | Stallmann, Hein P Faber, Chris Bronckers, Antonius LJJ Nieuw Amerongen, Arie V Wuisman, Paul IJM |
author_sort | Stallmann, Hein P |
collection | PubMed |
description | BACKGROUND: Polymethyl-methacrylate (PMMA) beads releasing antibiotics are used extensively to treat osteomyelitis, but require surgical removal afterwards because they do not degrade. METHODS: As an alternative option, this report compares the in vitro gentamicin release profile from clinically used, biodegradable carrier-materials: six injectable cements and six granule-types. Cement cylinders and coated granules containing 3% gentamicin were submerged in dH(2)O and placed in a 48-sample parallel drug-release system. At regular intervals (30, 90, 180 min. and then every 24 h, for 21 days), the release fluid was exchanged and the gentamicin concentration was measured. The activity of released gentamicin was tested on Staphylococcus aureus. RESULTS: All combinations showed initial burst-release of active gentamicin, two cements had continuous-release (17 days). The relative release of all cements (36–85%) and granules (30–62%) was higher than previously reported for injectable PMMA-cements (up to 17%) and comparable to other biodegradable carriers. From the cements residual gentamicin could be extracted, whereas the granules released all gentamicin that had adhered to the surface. CONCLUSION: The high release achieved shows great promise for clinical application of these biodegradable drug-carriers. Using the appropriate combination, the required release profile (burst or sustained) may be achieved. |
format | Text |
id | pubmed-1459860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-14598602006-05-13 In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile Stallmann, Hein P Faber, Chris Bronckers, Antonius LJJ Nieuw Amerongen, Arie V Wuisman, Paul IJM BMC Musculoskelet Disord Research Article BACKGROUND: Polymethyl-methacrylate (PMMA) beads releasing antibiotics are used extensively to treat osteomyelitis, but require surgical removal afterwards because they do not degrade. METHODS: As an alternative option, this report compares the in vitro gentamicin release profile from clinically used, biodegradable carrier-materials: six injectable cements and six granule-types. Cement cylinders and coated granules containing 3% gentamicin were submerged in dH(2)O and placed in a 48-sample parallel drug-release system. At regular intervals (30, 90, 180 min. and then every 24 h, for 21 days), the release fluid was exchanged and the gentamicin concentration was measured. The activity of released gentamicin was tested on Staphylococcus aureus. RESULTS: All combinations showed initial burst-release of active gentamicin, two cements had continuous-release (17 days). The relative release of all cements (36–85%) and granules (30–62%) was higher than previously reported for injectable PMMA-cements (up to 17%) and comparable to other biodegradable carriers. From the cements residual gentamicin could be extracted, whereas the granules released all gentamicin that had adhered to the surface. CONCLUSION: The high release achieved shows great promise for clinical application of these biodegradable drug-carriers. Using the appropriate combination, the required release profile (burst or sustained) may be achieved. BioMed Central 2006-02-26 /pmc/articles/PMC1459860/ /pubmed/16504140 http://dx.doi.org/10.1186/1471-2474-7-18 Text en Copyright © 2006 Stallmann et al; licensee BioMed Central Ltd. |
spellingShingle | Research Article Stallmann, Hein P Faber, Chris Bronckers, Antonius LJJ Nieuw Amerongen, Arie V Wuisman, Paul IJM In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile |
title | In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile |
title_full | In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile |
title_fullStr | In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile |
title_full_unstemmed | In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile |
title_short | In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile |
title_sort | in vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459860/ https://www.ncbi.nlm.nih.gov/pubmed/16504140 http://dx.doi.org/10.1186/1471-2474-7-18 |
work_keys_str_mv | AT stallmannheinp invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile AT faberchris invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile AT bronckersantoniusljj invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile AT nieuwamerongenariev invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile AT wuismanpaulijm invitrogentamicinreleasefromcommerciallyavailablecalciumphosphatebonesubstitutesinfluenceofcarriertypeondurationofthereleaseprofile |